Marie Perry

“For the second quarter, revenues exceeded $1 billion, and we're above the top end of our guidance range. Revenues for our commercial segment were $701.7 million, a slight decrease of 0.9% year-over-year.”

“So for the three-year target, so as reference, we had an investor day, highlighted our three-year targets, from an organic growth perspective, we have a CAGR of four to six percent.”

“For the first quarter, revenues totaled $968.3 million within our guidance range and consistent with the prior year period. Given the timing of the acquisition close, Quinox contributed less than one month to the quarterly results.”

“For the fourth quarter, revenues totals $980.1 million at the top end of our guidance range and relatively consistent with the prior year period. Revenues from our commercial segment were $698.6 million, an increase of 0.9% compared to the prior year and up 2.2% sequentially on a billable day adjusted basis.”

“For the third quarter, revenues totaled $1.01 billion, a decrease of 1.9% year over year but at the top end of our guidance expectations. Revenues from our commercial segment were $711.3 million, a decrease of 1% compared to the prior year.”